HH-009 / Huahui Health - LARVOL DELTA

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Huahui Health | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2029 ➔ Oct 2028

Enrollment open • Trial completion date • Hepatocellular Cancer • Oncology • Solid Tumor • FGF19

A randomized, open-label, multicenter phase Ib/II registration clinical trial to observe and evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of HH-009 injection in FGF19-positive advanced or unresectable hepatocellular carcinoma (HCC) subjects who have failed previous systemic treatment and progressed. (ChiCTR) - P1/2 | N=30 | Sponsor: Nanjing Tianyinshan Hospital; Nanjing Tianyinshan Hospital

New P1/2 trial • Hepatocellular Cancer • Oncology • Solid Tumor • FGF19

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Huahui Health

New P1/2 trial • Hepatocellular Cancer • Oncology • Solid Tumor • FGF19